An up-to-date evaluation of abiraterone for the treatment of prostate cancer

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Cancer of the Prostate. Cancer Stat Facts. SEER. cited 2020 Dec 27. Available from: https://seer.cancer.gov/statfacts/html/prost.html
   Google Scholar
• Parker C, Castro E, Fizazi K, et al. Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(9):1119–1134.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Prostate Cancer (Version 3.2020). cited Dec 30, 2020. Available from: http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
   Google Scholar
• Rice MA, Malhotra SV, Stoyanova T. Second-generation antiandrogens: from discovery to standard of care in castration resistant prostate cancer. Front Oncol. 2019;9. DOI:10.3389/fonc.2019.00801.
   Web of Science ®Google Scholar
• Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019;37(32):2974–2986.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Shore N, Tammela TL, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2019;380(13):1235–1246.
   PubMed Web of Science ®Google Scholar
• De Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995–2005. .
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, De Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138–148. .
   PubMed Web of Science ®Google Scholar
• Fizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352–360. .
   PubMed Web of Science ®Google Scholar
• Harris KA, Weinberg V, Bok RA, et al. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer. J Urol. 2002;168(2):542–545.
   PubMed Web of Science ®Google Scholar
• Lin G-W, Yao X-D, Ye D-W, et al. The prognostic factors of effective ketoconazole treatment for metastatic castration-resistant prostate cancer: who can benefit from ketoconazole therapy? Asian J Androl. 2012;14(5):732–737.
   PubMed Web of Science ®Google Scholar
• Stanbrough M, Bubley GJ, Ross K, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 2006;66(5):2815–2825.
   PubMed Web of Science ®Google Scholar
• Cai C, Chen S, Ng P, et al. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 Inhibitors. Cancer Res. 2011;71(20):6503–6513.
   PubMed Web of Science ®Google Scholar
• PubChem. Abiraterone acetate. Accessed Dec 17, 2020. https://pubchem.ncbi.nlm.nih.gov/compound/9821849
   Google Scholar
• Ang JE, Olmos D, De Bono JS. CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer. Br J Cancer. 2009;100(5):671–675.
   PubMed Web of Science ®Google Scholar
• Stuyckens K, Saad F, Xu XS, et al. Population pharmacokinetic analysis of abiraterone in chemotherapy-naïve and docetaxel-treated patients with metastatic castration-resistant prostate cancer. Clin Pharmacokinet. 2014;53(12):1149–1160.
   PubMed Web of Science ®Google Scholar
• Zytiga [Package Insert]. Janssen Biotech, Inc; 2020.
   Google Scholar
• Chi KN, Spratlin J, Kollmannsberger C, et al. Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer. J Clin Pharmacol. 2015;55(12):1406–1414.
   PubMed Web of Science ®Google Scholar
• Szmulewitz RZ, Peer CJ, Ibraheem A, et al. Prospective international randomized phase II study of low-dose abiraterone with food versus standard dose abiraterone in castration-resistant prostate cancer. J Clin Oncol. 2018;36(14):1389–1395.
   PubMed Web of Science ®Google Scholar
• Yonsa [Package Insert]. Sun pharma global; 2018.
   Google Scholar
• Stein CA, Levin R, Given R, et al. Randomized phase 2 therapeutic equivalence study of abiraterone acetate fine particle formulation vs. originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer: the STAAR study. Urol Oncol. 2018;36(2):81.e9–81.e16.
   Web of Science ®Google Scholar
• Marbury T, Lawitz E, Stonerock R, et al. Single-dose pharmacokinetic studies of abiraterone acetate in men with hepatic or renal impairment. J Clin Pharmacol. 2014;54(7):732–741.
   PubMed Web of Science ®Google Scholar
• Attard G, Reid AHM, Yap TA, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(28):4563–4571.
   PubMed Web of Science ®Google Scholar
• O’Donnell A, Judson I, Dowsett M, et al. Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer. 2004;90(12):2317–2325.
   PubMed Web of Science ®Google Scholar
• Danila DC, Morris MJ, De Bono JS, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(9):1496–1501.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13(10):983–992.
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16(2):152–160.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Tran N, Fein L, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20(5):686–700.
   PubMed Web of Science ®Google Scholar
• James ND, De Bono JS, Spears MR, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377(4):338–351. .
   PubMed Web of Science ®Google Scholar
• Khalaf DJ, Annala M, Taavitsainen S, et al. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. Lancet Oncol. 2019;20(12):1730–1739. .
   PubMed Web of Science ®Google Scholar
• Attard G, Merseburger AS, Arlt W, et al. Assessment of the safety of glucocorticoid regimens in combination with abiraterone acetate for metastatic castration-resistant prostate cancer: a randomized, open-label phase 2 study. JAMA Oncol. 2019;5(8):1159.
   PubMed Web of Science ®Google Scholar
• Colomba E, Marret G, Baciarello G, et al. Liver tests increase on abiraterone acetate in men with metastatic prostate cancer: natural history, management and outcome. Eur J Cancer Oxf Engl 1990. 2020;129:117–122.
   PubMed Web of Science ®Google Scholar
• Smith M, Parker C, Saad F, et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(3):408–419.
   PubMed Web of Science ®Google Scholar
• Ramamurthy C, Handorf EA, Correa AJ, et al. Cost-effectiveness of abiraterone versus docetaxel in the treatment of metastatic hormone naïve prostate cancer. Urol Oncol. 2019;37(10):688–695.
   PubMed Web of Science ®Google Scholar
• Sathianathen NJ, Alarid-Escudero F, Kuntz KM, et al. A cost-effectiveness analysis of systemic therapy for metastatic hormone-sensitive prostate cancer. Eur Urol Oncol. 2019;2(6):649–655.
   PubMed Web of Science ®Google Scholar
• Aguiar PN, Tan PS, Simko S, et al. Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer. Einstein. 2019;17:2.
   Web of Science ®Google Scholar
• Barqawi YK, Borrego ME, Roberts MH, et al. Cost-effectiveness model of abiraterone plus prednisone, cabazitaxel plus prednisone and enzalutamide for visceral metastatic castration resistant prostate cancer therapy after docetaxel therapy resistance. J Med Econ. 2019;22(11):1202–1209.
   PubMed Web of Science ®Google Scholar
• Ramaswamy K, Lechpammer S, Mardekian J, et al. Economic outcomes in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate plus prednisone. Adv Ther. 2020;37(5):2083–2097.
   PubMed Web of Science ®Google Scholar
• Gravis G, Boher J-M, Chen Y-H, et al. Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHAARTED and GETUG-AFU15 studies. Eur Urol. 2018;73(6):847–855.
   PubMed Web of Science ®Google Scholar
• Thiery-Vuillemin A, Poulsen MH, Lagneau E, et al. Impact of abiraterone acetate plus prednisone or enzalutamide on patient-reported outcomes in patients with metastatic castration-resistant prostate cancer: final 12-mo analysis from the observational AQUARiUS study. Eur Urol. 2020;77(3):380–387.
   PubMed Web of Science ®Google Scholar
• Khalaf DJ, Sunderland K, Eigl BJ, et al. Health-related quality of life for abiraterone plus prednisone versus enzalutamide in patients with metastatic castration-resistant prostate cancer: results from a phase II randomized trial. Eur Urol. 2019;75(6):940–947.
   PubMed Web of Science ®Google Scholar
• Iacovelli R, Ciccarese C, Bria E, et al. The cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer. Clin Genitourin Cancer. 2018;16(3):e645–e653.
   PubMed Web of Science ®Google Scholar
• WHO model list of essential medicines. cited 2021 Jan 11. Available from: https://www.who.int/publications-detail-redirect/WHOMVPEMPIAU2019.06
   Google Scholar